US Patent Litigations are now available. Check here

IP Verse

Celgene patent opposition analysis

Latest patents of Celgene opposed by its competitors

Explore Celgene's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jun 19, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3638243Aug 7, 2024Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia2
EP2498610Jun 19, 2024Selective Sphingosine 1 Phosphate Receptor Modulators And Methods Of Chiral Synthesis1
EP3782612Nov 8, 2023Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3370729Sep 27, 2023Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma1
EP2651400Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof1
EP3880802Sep 7, 2022Improved T Cell Manufacturing Process1
EP3782611Jul 6, 2022Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3692983Aug 11, 2021Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof6
EP3320902Feb 17, 2021Methods For Treating Diseases Using Isoindoline Compounds1
EP2797581May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione3

Top competitors of Celgene